Abstract
Objective To explore the significance of the aberrant expression phosphatase of regenerating liver-3 (PRL-3) and microRNA (miR)-17-92 family in colon cancer cells.Methods We stablely transfected PRL-3 expressing plasmid and empty plasmid into LoVo colon cancer cells and established two cell lines:LoVo-PRL-3 and LoVo-VC.MicroRNA chipset was used to investigate the aberrant expression of some oncomiRs.Two important members of miR-17-92 family:miR-17 and miR-19a were selected.quantitative real-time reverse transcription-polymerase chain reaction (qRT-PCR) was used to validate the expression of miR-17 and miR-19a in LoVo cells.RNA interference was used to knocked down STAT3 in LoVo-PRL-3 cells,after that the expression miR-17 and miR-19a were detected.Transient transfection of miR-17 and miR-19a mimic into LoVo-VC cells or transient transfection of miR-17 and miR-19a inhibitor into LoVo-PRL-3 cells were performed to evaluate the proliferation and invasive ability of these cells by cell counting kit-8 (CCK-8) proliferating assay and Transwell chamber assay.In 13 paired primary colon cancer tissues and metastatic lesions,immunohistochemistry was used to detect the expression of PRL-3 and pSTAT3 protein,while qRT-PCR was used to investigate the expression of PRL-3,miR-17 and miR-19a.Results In LoVo-PRL-3 cells,miR-17 and miR-19 were up-regulated significantly (P ＜ 0.05).Knockdown of STAT3 mRNA decreased the expression of miR-17 and miR-19.Over-expression of miR-17 and miR-19 promoted proliferation (P ＜0.05 and P ＜0.01) and invasion (P ＜0.01) of LoVo-VC cells,while knocking down of miR-17 and miR-19 inhibited proliferation and invasion of LoVo-PRL-3 cells (P ＜0.05).PRL-3 was elevated in metastatic lesions of colon cancer and positively correlated with pSTAT3,miR-17 and miR-19a.Conclusion PRL-3 promotes proliferation and invasion of colon cancer cells by up-regulation of the expression of miR-17 and miR-19a. Key words: Colon cancer; Phosphatase of regenerating liver-3; microRNA-17; microRNA-19a
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
